Neurogene Inc.
NASDAQ:NGNEBiotechnology
+$0.76 today
- Market cap
- $365.67M
- Beta
- 2.04
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$4.42
Volume 0.25M
Average 0.16M
NGNE Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Neurogene Inc.NASDAQ: NGNE
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $8.2M rose 0.5% year over year, behind the +8.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 34.3% from the prior quarter. Over 3 fiscal years it compounded at +40.7% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 9 analysts of $2.63M (-89.5%) for the fiscal year ending Dec 2026, a slowdown from the +11.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $8.2M+34.3% QoQ
- Last fiscal yearDec 2025
- $25.13M+11.1% YoY
- LTMMar 2026
- $27.57M+8.0% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 25.13M USD
- Year-over-year change
- +11.1%
- 4-year CAGR
- +32.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.13M | +11.1% |
| FY2024 | 2024-12-31 | 22.61M | +102.1% |
| FY2023 | 2023-12-31 | 11.19M | +24.2% |
| FY2022 | 2022-12-31 | 9.01M | +9.0% |
| FY2021 | 2021-12-31 | 8.27M | — |
Selling, General & Admin vs competitors
How NGNE compares with its peers on the latest reported figures
- NGNE's LTM Mar 2026 selling, general & admin of $27.57M is the 7th highest of the 8 companies compared; the peer median is $38.94M.
- Its year-over-year change of +8.0% is the 3rd highest of 8, against a peer median of -2.3%.
- Over three fiscal years its annual growth of +40.7% compares with a peer median of +4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $52.46M | -2.3% | +4.4% | 65.8% | |
| LTM Mar 2026 | $47.81M | -5.9% | +14.2% | 54.2% | |
| LTM Mar 2026 | $47.37M | -20.9% | -4.0% | 257.2% | |
| LTM Jun 2026 | $38.94M | +24.4% | -1.0% | 709.8% | |
| LTM Mar 2026 | $36.17M | -2.1% | +6.6% | 99.1% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $35.46M | -13.0% | +55.9% | — |
| LTM Mar 2026 | $27.57M | +8.0% | +40.7% | — | |
| LTM Mar 2026 | $20.62M | +11.6% | +2.3% | — | |
| Peer median (excluding NGNE) | $38.94M | -2.3% | +4.4% | 99.1% | |
Competitors are the stored peer set for NGNE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 925K | 0 |
| Cost of Revenue | 42.26M | 3.2M | 3.26M | 3.25M | 3.19M |
| Gross Profit | (42.26M) | (3.2M) | (3.26M) | (2.32M) | (3.19M) |
| Gross Margin | — | — | — | -251.0% | — |
| Research & Development | 42.26M | 47.51M | 44.39M | 60.92M | 75.01M |
| Selling, General & Admin | 8.27M | 9.01M | 11.19M | 22.61M | 25.13M |
| Operating Expenses | 8.27M | 53.32M | 52.32M | 80.28M | 100.02M |
| Depreciation & Amortization | 947K | 3.2M | 3.3M | 3.25M | 3.09M |
| EBITDA | (49.57M) | (51.99M) | (33.01M) | (71.89M) | (87.25M) |
| EBITDA Margin | — | — | — | -7771.4% | — |
| Operating Income | (50.53M) | (56.52M) | (55.58M) | (82.61M) | (103.21M) |
| Operating Margin | — | — | — | -8930.3% | — |
| Interest Income | 19K | 1.34M | 2.95M | 8.47M | 11.55M |
| Interest Expense | 0 | 2K | 12K | 12K | 5K |
| Other Income / Expenses | 17K | 1.33M | 19.27M | 7.46M | 12.86M |
| Income Before Tax | (50.52M) | (55.19M) | (36.32M) | (75.14M) | (90.35M) |
| Pre-Tax Margin | — | — | — | -8123.7% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.52M) | (55.19M) | (36.32M) | (75.14M) | (90.35M) |
| Net Margin | — | — | — | -8123.7% | — |
| EPS (Basic) | (0.92) | (4.30) | (2.83) | (4.28) | (4.24) |
| EPS (Diluted) | (0.92) | (4.30) | (2.83) | (4.28) | (4.24) |
| Weighted Avg Shares | 55.04M | 12.82M | 12.82M | 17.57M | 21.17M |
| Weighted Avg Shares (Diluted) | 55.04M | 12.82M | 12.82M | 17.57M | 21.17M |
Neurogene Inc.
NASDAQ:NGNE
Intrinsic Alpha fair value
Locked
Current Price
$23.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.